Skip to main content
. 2016 Dec 27;1(3):265–269. doi: 10.1182/bloodadvances.2016000034

Table 1.

Summary of published trials of anti-CD19 immunotherapies of B-ALL

Agent Population N CR rate (%) Comment Enrolled patients with MRD only? sCRS sCNS Reference
Blinatumomab Ph−, primary R/R ALL adult patients 189 43 Phase 2 Not reported 2% 13% 26
Blinatumomab Adults >65 R/R B-ALL 261 47 No response difference based on age >65 vs <65 y Not reported 5 41 12
Blinatumomab Pediatric R/R ALL 31 31 Phase 2 Unknown 5 5
Blinatumomab Pediatric R ALL 9 44 CR reported for primary response (1 cycle) Unknown 22 33 4
Blinatumomab Adults, primary R/R ALL 36 69 Phase 2 No <1 17 27
CAR-T 4-1BB Children and adults, R/R ALL 30 90 Yes 27 43 21
CAR-T CD28 Children R/R ALL 20 70 Yes 29 <1 3
CAR-T CD28 R/R B-ALL 16 88 Yes 44 31 8
CAR-T 4-1BB Adults R/R B-ALL 29 93 Yes 23 50 28
CAR-T Adults R/R B-ALL 32 91 Yes 22 29
CAR-T Pediatric R/R B-ALL 37 91 Unknown 30
CAR-T 4-1BB (humanized) Pediatric R/R B-ALL 6 50 Unknown 31

MRD, minimal residual disease; R/R, relapsed/refractory; sCNS, severe neurologic adverse events, grade 3 or above; sCRS, severe cytokine release syndrome, grade 3 or above.